GlassScriptPhysician profile
Francois M Vachon
NPI 1104861293
$6,147.82
in general payments reported to CMS, 2019-2025
41 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $1,402 · 2021: $1,613 · 2022: $1,157 · 2023: $206 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,207.37 | 2019-2022 | |
| Novo Nordisk INC | $761.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $753.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.49 | 2019-2025 | Jardiance |
| Abbvie INC. | $372.28 | 2019-2023 | Vraylar, Synthroid, Qulipta |
| Janssen Pharmaceuticals, INC | $210.36 | 2019-2022 | |
| Amarin Pharma, INC. | $197.66 | 2019-2022 | |
| Esperion Therapeutics, INC. | $182.53 | 2020-2022 | |
| Pfizer INC. | $151.73 | 2019-2020 | |
| Amgen INC. | $143.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $135.97 | 2019-2021 | |
| Lilly USA, LLC | $129.82 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $128.20 | 2021 | |
| Boston Scientific Corporation | $113.96 | 2020 | |
| Phathom Pharmaceuticals, INC. | $113.03 | 2025 | Voquezna |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francois Vachon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.